Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 4/20 | 0.54 |
| ▸ | CHRNA4 | P43681 | 4/20 | 0.54 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.46 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.46 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.46 |
| ▸ | CHRNB4 | P30926 | 3/20 | 0.46 |
| ▸ | CHRNA3 | P32297 | 3/20 | 0.46 |
| ▸ | CHRNA1 | P02708 | 1/20 | 0.46 |
| ▸ | CHRNB1 | P11230 | 1/20 | 0.46 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.46 |
| ▸ | CHRNB3 | Q05901 | 1/20 | 0.46 |
| ▸ | GRIN1 | Q05586 | 2/20 | 0.44 |
| ▸ | GRIN2B | Q13224 | 2/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6311327 | 0.89 | CHRNB2 (0.54) | CHRNB2CHRNA4CHRM2CHRM1CHRM3 | |
| SCHEMBL6306245 | 0.89 | CHRNB2 (0.54) | CHRNB2CHRNA4CHRM2CHRM1CHRM3 | |
| SCHEMBL24521960 | 0.89 | CHRNB2 (0.54) | CHRNB2CHRNA4CHRM2CHRM1CHRM3 | |
| SCHEMBL1936160 | 0.85 | CHRM2 (0.62) | CHRNB2CHRNA4CHRM2CHRM1CHRM3 | |
| SCHEMBL7237136 | 0.83 | CHRNB2 (0.55) | CHRNB2CHRNA4CHRNB4CHRNA3CHRNA1 | |
| SCHEMBL7530388 | 0.83 | CHRNB2 (0.55) | CHRNB2CHRNA4CHRNB4CHRNA3CHRNA1 | |
| SCHEMBL20069120 | 0.83 | CHRNB2 (0.54) | CHRNB2CHRNA4GRIN1GRIN2B | |
| SCHEMBL14805856 | 0.82 | CHRNB2 (0.50) | CHRNB2CHRNA4CHRNB4CHRNA3CHRNA1 | |
| SCHEMBL20147427 | 0.82 | CHRNB2 (0.50) | CHRNB2CHRNA4CHRNB4CHRNA3GRIN1 | |
| SCHEMBL6123545 | 0.80 | HRH3 (0.51) | CHRNB2CHRNA4GRIN1GRIN2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3534901-B1 | POSITIVE ALLOSTERIC MODULATORS OF THE MUSCARINIC ACETYLCHOLINE RECEPTOR M4 | UNIV VANDERBILT (US) | 2022-06-22 | — | — | EP | disclosed |
| US-20170037059-A1 | GYRASE INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2017-02-09 | — | — | US | disclosed |
| US-9481675-B2 | Gyrase inhibitors | MERCK SHARP & DOHME CORP. (US) | 2016-11-01 | — | — | US | disclosed |
| US-20130079323-A1 | GYRASE INHIBITORS | TRIUS THERAPEUTICS, INC. (US) | 2013-03-28 | — | — | US | disclosed |
| WO-2011032050-A2 | GYRASE INHIBITORS | TRIUS THERAPEUTICS, INC. (US) | 2011-03-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170037059-A1 | GYRASE INHIBITORS | TOP1, CA7, TOP2B | CHRNB2 2210/4885CHRNA4 2272/4885CHRM2 1809/4885 |
| US-20130079323-A1 | GYRASE INHIBITORS | TOP1, CA7, TOP2B | CHRNB2 2210/4885CHRNA4 2272/4885CHRM2 1809/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.